Expanded pharmacy distribution of Peptonic’s VagiVital[®]

Report this content

Stockholm, December 19th, 2019 - Peptonic Medical AB (‘Peptonic’ or ‘Company’) today announces that Kronans Apotek and Apoteksgruppen have decided to carry Peptonic’s self-care product VagiVital® in 170 and 37 of their pharmacy retail shops, respectively, from w/c February 10th, 2020. Until now, VagiVital® has been available for purchase on the webshop of Kronans Apotek and on order in Apoteksgruppen’s pharmacies. However, from mid February the availability of VagiVital® will be considerably improved in these pharmacies.

In addition to now being for sale in Kronans Apotek and Apoteksgruppen, VagiVital® can be purchased in 280 of Apoteket AB’s pharmacy retail shops and in its webshop, and from the webshops of Apoteket Hjärtat (www.apotekhjartat.se) and Kronans Apotek (www.kronansapotek.se) , and on www.apotea.sewww.meds.sewww.apotek365.se and www.apohem.se.

Efforts to further expand the distribution of VagiVital® to even more pharmacy retail shops are ongoing. In Norway and Denmark, VagiVital® is sold on-line through its own webshops. In April this year, Orion Pharma Oy launched VagiVital® in Finland under its own trade mark, Femisan Vital.

For more information, please contact;

Johan Inborr, CEO

Mobile: +46 708 853 893

E-mail:  johan.inborr@peptonicmedical.se

This information is information that Peptonic Medical AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 19th December 2019.

About VagiVital®

VagiVital®is a patent pending hormone free self-care product for the treatment of vaginal atrophy and vaginal dryness. The product has been tested in randomised clinical studies (vaginal atrophy) with very positive results both for objective (vaginal pH and proportion of superficial cells in the vaginal mucosa) and subjective (most bothersome symptoms, such as vaginal dryness, vaginal irritation/itching, dyspareunia and dysuria) parameters. The magnitude of symptom relief is on par with that demonstrated with e.g. prescription estrogen based products on the market today. It was very well tolerated and caused no serious adverse effects. 

VagiVital®was launched in Sweden as a non-prescription self-care product in July 2018 (see www.vagivital.com). 

About Peptonic Medical

Peptonic Medical is an innovative Swedish medical development company. Its vision is to offer safe and effective treatments and relief for women specific diseases and medical conditions.

VagiVital®is a registered trademark of Peptonic Medical. The product is hormone free and is being commercialised for the non-prescription use for the treatment of vaginal atrophy (VA) and vaginal dryness. The pipeline of Peptonic Medical also includes Vagitocin®, which is an oxytocin-based vaginal gel for the treatment of VA. This product candidate is in clinical development phase 2. The development of Vagitocin® is on hold pending additional data on i.a. the mechanism of action.

Since July 2014, the Peptonic Medical share has been traded on the Spotlight Stock Exchange (www.spotlight.se, ticker: PMED) in Stockholm, Sweden. 

For more information:www.peptonicmedical.com